TScan Therapeutics, Inc. - Common Stock — 四半期キャッシュフロー (NASDAQ:TCRX) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

総資産 371.12 M332.71 M298.56 M262.23 M228.79 M201.99 M 負債合計 130.15 M122.51 M121.85 M118.2 M105.67 M105.07 M 純資産合計 240.97 M210.2 M176.71 M144.02 M123.12 M96.92 M 負債および純資産合計 371.12 M332.71 M298.56 M262.23 M228.79 M201.99 M 有利子負債合計 32.07 M32.18 M32.3 M32.41 M32.53 M32.65 M 純負債 32.07 M32.18 M-185.75 M-152.04 M-119.87 M-95.4 M

ニュース

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com

【決算速報】Tscan Therapeutics、売上高は予想を上回り、利益は予想を上回る結果に

Tscan Therapeutics earnings beat by $0.09, revenue topped estimates

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan completes enrollment in trial cohort, receives FDA clearance

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Tscan Therapeutics株式、ASHイベント後もBTIGからニュートラル評価を維持